# US 2006/0154883 A1 · Nonsense-mediated mrna decay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154883 A1
- Document ID: US20060154883A1
- Status: Published application
- Kind: A1
- Application number: 10/525,273
- Filed: 2003-08-21
- Published: 2006-07-13
- Earliest claimed: 2002-08-22
- Inventors: Lynne Maquat
- Web page: https://patentgrep.com/patent/US20060154883A1

## CPC

- C07K 14/47: from mammals
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/53: partially self-complementary or closed
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are compositions and methods relating to nonsense mediated decay (NMD) particularly in the “pioneer” round of translation. The present invention provides methods of treating disorders relating to NMD and methods of screening substances for use in the study of or treatment of conditions relating to NMD.

## Claims

### Claim 1

A method of treating a disorder in a subject comprising administering to the subject a substance, wherein the substance modulates of nonsense-mediated mRNA decay in the pioneer round of translation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disorder is an inherited genetic disorder.

### Claim 3 (depends on 2)

The method of claim 2, wherein the genetic disorder can be selected from the group consisting of cystic fibrosis, hemophilia, mucopolysaccharidoses, muscular dystrophy, anemia, glycolytic enzyme deficiency, connective tissue disorder, DNA repair disorder, dementia, Sandhoff disease, epidermolysis bullosa simplex, insulin resistance, maple syrup urine disease, hereditary fructose intolerance, inherited immunodeficiency, inherited cancer, carbohydrate metabolism disorder, amino acid metabolism disorder, lipoprotein metabolism disorder, lipid metabolism disorder, lysomal enzymes disorder, steroid metabolism disorder, purine metabolism disorder, pyrimidine metabolism disorder, metal metabolism disorder, porphyrin metabolism disorder, and heme metabolism disorder.

### Claim 4 (depends on 1)

The method of claim 1, wherein the disorder is an acquired disorder.

### Claim 5 (depends on 4)

The method of claim 4, wherein the acquired disorder is a mutation in p53.

### Claim 6 (depends on 4)

The method of claim 4, wherein the acquired disorder is a mutation in BRCA-1.

### Claim 7 (depends on 4)

The method of claim 4, wherein the acquired disorder is a cancer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cancer is selected from the group consisting of lymphoma, B cell lymphoma, T cell lymphoma, leukemia, carcinoma, sarcoma, glioma, blastoma, neuroblastoma, plasmacytoma, histiocytoma, melanoma, adenoma, mycosis fungoide, hypoxic tumor, myeloma, metastatic cancer, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, colon cancer, cervical cancer, cervical carcinoma, breast cancer, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, hematopoietic cancers, testicular cancer, colorectal cancer, and prostatic cancer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 10 (depends on 1)

The method of claim 1, wherein the modulation is a decrease in nonsense-mediated mRNA decay.

### Claim 11 (depends on 1)

The method of claim 1, wherein the modulation is an increase in nonsense-mediated mRNA decay.

### Claim 12 (depends on 1)

The method of claim 1, wherein the substance interacts with Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, or Rrp41.

### Claim 13 (depends on 1)

The method of claim 1, wherein the substance is a functional nucleic acid, siRNA, peptide, protein, antibody, or chemical.

### Claim 14

A method of screening for a substance that modulates a nonsense-mediated mRNA decay (NMD) complex comprising
(a) incubating the substance with the complex, and
(b) assaying for a change in NMD, an increase or decrease in NMD activity indicating a modulating substance.

### Claim 15 (depends on 14)

The method of claim 14, wherein the complex comprises Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 16 (depends on 14)

The method of claim 14, wherein the complex comprises one or more of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hsmg5Sc, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 17 (depends on 14)

The method of claim 14, wherein the complex comprises at least two members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 18 (depends on 14)

The method of claim 14, wherein the complex comprises at least three members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 19 (depends on 14)

The method of claim 14, wherein the complex comprises at least four members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 20 (depends on 14)

The method of claim 14, wherein the complex comprises at least five members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 21 (depends on 14)

The method of claim 14, wherein the complex comprises at least six members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 22 (depends on 14)

The method of claim 14, wherein the complex comprises at least seven members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 23 (depends on 14)

The method of claim 14, wherein the complex comprises at least eight members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 24 (depends on 14)

The method of claim 14, wherein the complex comprises at least nine members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 25 (depends on 14)

The method of claim 14, wherein the complex comprises at least ten members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 26 (depends on 14)

The method of claim 14, wherein the complex comprises at least eleven members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 27 (depends on 14)

The method of claim 14, wherein the complex comprises at least twelve members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 28 (depends on 14)

The method of claim 14, wherein the complex comprises at least thirteen members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 29 (depends on 14)

The method of claim 14, wherein the complex comprises at least fourteen members of the group consisting of Upf2, Upf3, Upf3X, PABP2, CBP20, CBP80, hSmg5/7a, hSmg5/7b, hSmg5/7c, Dcp2, PM/Scl100, poly (A) ribonuclease (PARN), Rat1, Xrn1, and Rrp41.

### Claim 30

A method of screening for a substance that modulates nonsense-mediated mRNA decay (NMD) comprising
(a) incubating the substance with a stably transfected cell comprising a reporter gene with a nonsense-mutation, and
(b) assaying the amount of NMD in the cell, wherein a increase or decrease in the amount of mRNA relative to the amount of mRNA in the absence of the substance indicates a substance that modulates NMD activity.

### Claim 31

A method of screening for a substance that inhibits nonsense-mediated mRNA decay (NMD) comprising
(a) incubating the substance with Upf2 and Upf3 forming a substance-Upf2-Upf3 mixture, and
(b) assaying the amount of Upf2-Upf3 complex present in the mixture, wherein a decrease in the amount of Upf2-Upf3 complex relative to the amount of Upf2-Upf3 complex in the absence of the substance indicates that the substance inhibits NMD.

### Claim 32 (depends on 31)

The method of claim 31, wherein the Upf2 has at least 80%, 85%, 90%, or 95% identity to the sequence set forth in ATCC No. AF318574, or fragment thereof.

### Claim 33 (depends on 31)

The method of claim 31, wherein the Upf3 has at least 80%, 85%, 90%, or 95% identity to the sequence set forth in ATCC No. AF318575, or fragment thereof.

### Claim 34

A method of screening for a substance that inhibits nonsense-mediated mRNA decay (NMD) comprising
(a) incubating the substance with Upf2 and Upf3X forming a substance-Upf2-Upf3X mixture, and
(b) assaying the amount of Upf2-Upf3X complex present in the mixture, wherein a decrease in the amount of Upf2-Upf3X complex relative to the amount of Upf2-Upf3X complex in the absence of the substance indicates that the substance inhibits NMD.

### Claim 35 (depends on 34)

The method of claim 34, wherein the Upf2 has at least 80%, 85%, 90%, or 95% identity to the sequence set forth in ATCC No.:AF318574 or a fragment thereof.

### Claim 36 (depends on 34)

The method of claim 34, wherein the Upf3X has at least 80%, 85%, 90%, or 95% identity to the sequence set forth in ATCC No.:AF318576 or a fragment thereof.

### Claim 37

A method of screening for a substance that modulates nonsense-mediated mRNA decay (NMD) comprising,
a) administering a substance to a system, wherein the system comprises the components essential for NMD activity, and
b) assaying the effect of the substance on the amount of NMD activity in the system, wherein a substance which causes a change in the amount of NMD activity present in the system compared to the amount of NMD activity in the system in the absence of composition is a modulator.

### Claim 38 (depends on 37)

A method of modulating nonsense-mediated mRNA decay (NMD) activity comprising administering a substance, wherein the substance is identified by the method of claim 37.

### Claim 39 (depends on 29)

A method of making a substance capable of modulating nonsense-mediated mRNA decay (NMD) activity comprising admixing a substance identified by the method of claim 29 with a pharmaceutically acceptable carrier.

### Claim 40 (depends on 39)

A substance made by the method of claim 39.

### Claim 41

A method of making a modulator of nonsense-mediated mRNA decay (NMD) comprising,
a) administering a substance to a system, wherein the system comprises NMD activity,
b) assaying the effect of the substance on the amount of NMD activity in the system,
c) selecting a substance which causes a change in the amount of NMD activity present in the system compared to the amount of NMD activity in the system in the absence of substance, and
d) synthesizing the substance.

### Claim 42

A substance that modulates NMD in the pioneer round of translation.

### Claim 43 (depends on 42)

The substance of claim 42, wherein the substance is an antibody that modulates NMD.

### Claim 44 (depends on 43)

The substance of claim 43, wherein the antibody binds Upf2.

### Claim 45 (depends on 43)

The substance of claim 43, wherein the antibody binds Upf3.

### Claim 46 (depends on 43)

The substance of claim 43, wherein the antibody binds Upf3X.

### Claim 47 (depends on 43)

The substance of claim 43, wherein the antibody binds PABP2.

### Claim 48 (depends on 43)

The substance of claim 43, wherein the antibody binds PARN.

### Claim 49 (depends on 43)

The substance of claim 43, wherein the antibody binds Dcp2.

### Claim 50 (depends on 43)

The substance of claim 43, wherein the antibody binds PM/Scl100.

### Claim 51 (depends on 43)

The substance of claim 43, wherein the antibody binds Rat1.

### Claim 52 (depends on 43)

The substance of claim 43, wherein the antibody binds Xrn1.

### Claim 53 (depends on 43)

The substance of claim 43, wherein the antibody binds Rrp41.

### Claim 54 (depends on 43)

The substance of claim 43, wherein the antibody binds hSmg5/7a.

### Claim 55 (depends on 43)

The substance of claim 43, wherein the antibody binds hSmg5/7b.

### Claim 56 (depends on 43)

The substance of claim 43, wherein the antibody binds hSmg5/7c.

### Claim 57 (depends on 42)

The substance of claim 42, wherein the substance is a vector comprising a nucleic acid that encodes a protein that modulates NMD.

### Claim 58

A vector comprising a nucleic acid that encodes a protein that modulates NMD.

### Claim 59 (depends on 57)

A cell comprising the vector of claim 57.

### Claim 60 (depends on 42)

The substance of claim 42, wherein the substance is siRNA that modulates NMD.

### Claim 61 (depends on 60)

The substance of claim 60, wherein the siRNA binds Upf2.

### Claim 62 (depends on 60)

The substance of claim 60, wherein the siRNA binds Upf3.

### Claim 63 (depends on 60)

The substance of claim 60, wherein the siRNA binds Upf3X.

### Claim 64 (depends on 60)

The substance of claim 60, wherein the. siRNA binds PABP2.

### Claim 65 (depends on 60)

The substance of claim 60, wherein the siRNA binds PARN.

### Claim 66 (depends on 60)

The substance of claim 60, wherein the siRNA binds Dcp2.

### Claim 67 (depends on 60)

The substance of claim 60, wherein the siRNA binds PM/Scl100.

### Claim 68 (depends on 60)

The substance of claim 60, wherein the siRNA binds Rat1.

### Claim 69 (depends on 60)

The substance of claim 60, wherein the siRNA binds Xrn1.

### Claim 70 (depends on 60)

The substance of claim 60, wherein the siRNA binds Rrp41.

### Claim 71 (depends on 60)

The substance of claim 60, wherein the siRNA binds hSMg5/7a.

### Claim 72 (depends on 60)

The substance of claim 60, wherein the siRNA binds hSmg5/7b.

### Claim 73 (depends on 60)

The substance of claim 60, wherein the siRNA binds hSmg5/7c.
